

Allergy Testing

JAMES T. LI, M.D., PH.D., Mayo Clinic and Foundation, Rochester, Minnesota

Percutaneous and intradermal skin tests and laboratory assays of specific IgE antibodies may be useful in selected cases of allergy management. Percutaneous testing kits are available from various manufacturers. A number of common allergens are available in standardized preparations. Positive and negative skin controls are important in establishing reliable results. Antihistamine medications can interfere with skin testing and should be stopped beforehand. Serious reactions to skin testing are rare. Establishing the sensitivity and specificity of percutaneous testing is difficult because there is no widely accepted gold standard for defining a true allergic reaction. Intradermal testing is more sensitive than percutaneous methods but much less specific. Its use is restricted to testing for allergy to insect stings or penicillin. In cases where skin testing is not available or desirable, laboratory assays for IgE antibodies to specific allergens may be used. These assays are generally less sensitive than skin testing methods. Selected patients with allergic rhinitis or asthma that is not controlled with standard therapy may benefit from allergy testing, especially when it can target allergen avoidance measures or guide immunotherapy. (Am Fam Physician 2002;66:621-4,626. Copyright © 2002 American Academy of Family Physicians.)

 A patient information handout on allergy testing, written by the author, is provided on page 626.

Allergic diseases are among the most common medical problems encountered in ambulatory practice. However, some patients with suspected allergic disease turn out, on further evaluation, to have a medical problem that cannot be attributed to an allergy. Allergy testing can help the physician determine if a patient's problem is caused by an allergy and identify the specific problem allergens (Table 1). Having established a correct allergy diagnosis, the physician is better equipped to select appropriate therapeutic interventions for that

patient, such as allergen avoidance, medications, and, sometimes, immunotherapy (Table 2). For example, a patient with a specific pollen allergy may be instructed to increase medication use during the pollen season. Patients with an animal allergy may be instructed to use allergy or asthma medication before exposure.

There are several types of specific allergy tests. Immediate-type hypersensitivity (IgE) skin tests are typically used to test for airborne allergens, foods, insect stings, and penicillin. Immediate-type hypersensitivity also can be evaluated through serum IgE antibody testing called radioallergen sorbent testing (RAST). Delayed-type hypersensitivity skin tests (patch-type skin tests) are commonly used in patients with suspected contact dermatitis. Some common allergens for patch testing are rubber, medications, fragrances, vehicles or preservatives, hair dyes, metals, and resins. This review focuses on immediate-type hypersensitivity skin testing and serum IgE antibody testing.

Immediate-Type Hypersensitivity Skin Testing

Immediate-type hypersensitivity skin testing is most commonly used in the diagnosis of allergic rhinitis, allergic asthma, food allergy, penicillin allergy, and stinging-

TABLE 1
Major Indications for Allergy Testing

Condition	Major indication
Rhinitis	Symptoms not controlled by medications and allergen avoidance
Asthma	Persistent asthma in patients exposed to perennial indoor allergens
Suspected food allergy	Previous suspected systemic reaction to food
Suspected drug allergy	Previous suspected systemic reaction to drug, and clinical indication for suspected drug
Suspected insect sting	Previous suspected systemic reaction to insect sting

See page 677 for definitions of strength-of-evidence levels contained in this article.

TABLE 2

Management Principles of Allergic Conditions

<i>Condition</i>	<i>Management modalities</i>
Allergic rhinitis	Environmental interventions to reduce allergen exposure, medications, immunotherapy
Allergic asthma	Environmental interventions to reduce allergen exposure, medications, immunotherapy
Food allergy	Dietary modification, self-administered epinephrine for reaction
Drug allergy	Avoidance of suspected drug, drug desensitization
Insect-sting allergy	Precautions to reduce insect exposure, immunotherapy, self-administered epinephrine for reactions

insect hypersensitivity. Skin testing can be performed by the percutaneous route (diluted allergen is pricked or scratched into the skin surface) and by the intradermal route (injection of allergen within the dermal layer).

PERCUTANEOUS TESTING

Several types of skin testing instruments are available for percutaneous skin testing. Each brand of instrument has its own sensitivities and specificities. Positive-control skin tests (histamine) and negative-control skin tests (diluent) are essential for correct interpretation of skin test reactions. About 15 minutes after the application of allergen to skin, the test site is examined for a wheal and flare reaction. A positive skin test reaction (typically, a wheal 3 mm greater in diameter than the negative control reaction, accompanied by surrounding erythema) reflects the presence of mast cell-bound IgE specific to the tested allergen.

Antihistamines interfere with the development of the wheal and flare reaction and should be stopped before immediate-type skin testing. First-generation antihistamines may be stopped two to three days before testing, but the newer, second-generation antihistamines can affect skin testing results for three to 10 days or longer.¹ Medications with antihistamine properties, such as anticholinergic agents, phenothiazine, and tricyclic antidepressants, also should be discontinued before skin testing. Histamine

H₂-receptor antagonists (e.g., cimetidine [Tagamet], ranitidine [Zantac]) have a limited inhibitory effect; these medications may be stopped on the day of skin testing.¹ Inhaled and short-term systemic corticosteroids generally do not significantly suppress the wheal and flare reaction of immediate-type skin tests.

Immediate-type skin testing is a safe procedure with a very small risk of systemic reaction. A retrospective study² involving 18,311 patients found six mild systemic reactions over a five-year period. A nationwide survey of allergy specialists reported six fatal reactions to skin tests from 1945 to 1986.³

Allergy to airborne substances (i.e., allergic rhinitis and asthma) is typically evaluated using a panel of percutaneous skin tests for about 40 allergens. A number of the most commonly used allergenic extracts for skin tests are now standardized (Table 3). Percutaneous skin testing has been used to test for food allergy; however, it is less reliable for evaluating food allergy than for evaluating reaction to airborne allergens.

Analysis of the clinical performance of percutaneous testing for establishing an allergy diagnosis is limited by the lack of a universal gold standard to confirm a specific allergy. Clinical studies suggest that the medical history is generally inadequate to serve as a gold standard.^{4,5} Experimental trials where allergy exposure is carefully controlled provide better data about percutaneous testing.

In a recently published trial,⁶ patients with suspected cat allergy were tested through enclosure in a small room containing two cats. During a one-hour exposure, the study subjects were monitored for upper respiratory symptoms, lower respiratory symptoms, and spirometry changes. Each patient also underwent percutaneous testing. The sensitivity and specificity of percutaneous testing were 94 and 80 percent for upper respiratory symptoms, respectively; 84 and 87 percent for lower respiratory symptoms; and 97 and 81 percent for decreased forced expiratory volume in one second (a 15 percent fall or greater). A negative result for percutaneous testing indicated that a true cat allergy was unlikely.

The performance of percutaneous tests in the diagnosis of food allergy also has been widely investigated. In a study⁷ where the gold standard for allergy was a double-blind food challenge to the suspected allergen (e.g., egg, milk, peanut, soy, wheat, or fish), the sensitivity of percutaneous tests was 76 to 98 percent, with specificity ranging

The Author

JAMES T. LI, M.D., PH.D., is currently professor of medicine at the Mayo Clinic, Rochester, Minn. He received his medical degree from Duke University School of Medicine, Durham, N.C. He earned a doctorate in microbiology and immunology at Duke University Graduate School, Durham.

Address correspondence to James T. Li, M.D., Ph.D., Mayo Clinic and Foundation, 200 First St. S.W., Rochester, MN 55905 (e-mail: li.james@mayo.edu). Reprints are not available from the author.

TABLE 3
Standardized Extracts for Allergy Skin Testing

Cat hair	June grass
Cat pelt	Perennial rye grass
Dust mite (<i>Dermatophagoides farinae</i>)	Orchard grass
Dust mite (<i>Dermatophagoides pteronyssinus</i>)	Timothy grass
Bermuda grass	Sweet vernal grass
Red top grass	Short ragweed

NOTE: Many other nonstandardized allergens are available for skin testing.

from 29 to 57 percent, depending on the food extract used for testing.

The specificity for food allergen tests is generally low, partly because of cross reactions between some food groups (e.g., legumes). Negative reactions to suggested food allergens on percutaneous tests make a diagnosis of true food allergy unlikely in most cases; however, the poor specificity of these tests precludes a definitive diagnosis of food allergy based on positive test results alone. A double-blind food challenge should be considered when more clinical certainty is needed in diagnosing a serious food allergy.

INTRADERMAL TESTING

Intradermal tests are much more sensitive than percutaneous methods (the tested allergen is 10- to 100-fold more diluted), but they have a lower specificity. Intradermal testing is usually reserved for venom and penicillin allergy testing when percutaneous tests are negative but there is high clinical suspicion of allergy.

Stinging-Insect Hypersensitivity. Adults who present with a history of a systemic reaction to insects (e.g., bee, yellow jacket, hornet, wasp, fire ant) should be evaluated with allergy skin tests. Children who present with only dermatologic manifestations of a systemic reaction are not at substantially increased risk for future anaphylaxis and do not need allergy skin tests. Management of sensitive patients may include education, avoidance measures, self-administered epinephrine, and allergen immunotherapy.

Drug Allergy. Reliable allergy tests for drugs are available only for penicillin and local anesthetics. In many patients with a history of penicillin allergy, the simplest course is to prescribe an antimicrobial agent that does not contain a beta-lactam ring. In patients with a history of penicillin allergy who have a strong indication for use of a beta-lactam antibiotic, penicillin skin tests can be helpful.

A large study of patients with penicillin allergy showed that 1,220 of 1,227 patients (99 percent) with intradermal skin tests negative to penicillin did not experience a drug reaction when given penicillin.⁸ [Evidence level B, non-

randomized clinical trial] Of the nine patients with positive penicillin skin tests who received penicillin, two (22 percent) developed a drug reaction. In a similar but smaller study,⁹ 96 percent of patients with negative penicillin skin tests had no reaction when given penicillin, and 50 percent of patients with positive penicillin skin tests developed a drug reaction when given penicillin. [Evidence level B, nonrandomized clinical trial]

These results suggest that penicillin can be given safely to patients with negative intradermal skin tests to penicillin. Patients with positive penicillin skin tests may be at increased risk for drug reaction, but the specificity of intradermal testing is low.

Assays for Specific IgE Antibodies

Although widely used in the past, serum measurement of the total IgE level is unhelpful in the diagnosis of allergy. Of more clinical use are assays for specific IgE antibodies to suspected allergens.

Assays for IgE antibodies specific to common airborne and food allergens are readily available. IgE antibody tests for venom and drugs have less clinical utility and are not routinely used. RAST was the first widely employed method of detecting IgE antibodies in blood that are specific for a given allergen. Several closely related variants are marketed (e.g., modified RAST, Quidel QuickVue One-Step Allergen screen, Pharmacia Immucap). Quantitative assays that include a reference curve calibrated against standardized IgE are preferred. It is important to select a reliable laboratory to perform RAST testing.

In general, RAST and other laboratory methods for IgE testing are highly specific but somewhat less sensitive than percutaneous tests. Results of laboratory testing for food-specific IgE are generally poor, even less helpful than those for percutaneous skin testing.

RAST or other laboratory testing is typically considered when skin testing is inconvenient or difficult to perform. Most primary care physicians do not have immediate access to a clinical skin testing laboratory, so RAST may be

The low specificity of percutaneous testing for food allergens precludes a diagnosis of food allergy based on a positive skin test alone. A double-blind food challenge should be considered.

Allergy Testing

easier to obtain. Some patients cannot undergo skin testing because of skin disease that would obscure wheal and flare results (e.g., extensive atopic dermatitis) or because they cannot stop taking medications that suppress the skin test response. In cases of life-threatening allergy (e.g., anaphylaxis), laboratory testing is sometimes used as a proxy result, keeping in mind its limited sensitivity.

Allergic Rhinitis

The most common allergy-mediated clinical problem where specific testing may be needed is chronic rhinitis. The differential diagnosis of chronic rhinitis (nasal congestion, rhinorrhea, sneezing) includes allergic rhinitis, nonallergic inflammatory rhinitis, and rhinitis from a noninflammatory process, such as vasomotor rhinitis.

Many physicians make a presumptive diagnosis of allergic rhinitis based on the medical history. Management of these patients may include use of antihistamines, decongestants, or intranasal steroids. This is a reasonable and effective approach in many patients. In patients with significantly discomforting or disabling symptoms that are not controlled with standard measures, specific allergy testing may be warranted.

Percutaneous testing can help establish the correct diagnosis and identify the offending allergens (pollen, mold spores, dust mites, cockroaches, or household pets). Allergen avoidance measures often are difficult to implement and costly. After specific testing, avoidance measures can be targeted to allergens to which the patient is known to be allergic.

Allergen immunotherapy is another option in refractory cases of allergic rhinitis not amenable to the usual control measures. Like allergen avoidance, it can involve a lot of labor and expense. Specific allergy testing can identify patients likely to benefit from immunotherapy and provide guidance about which allergens to include in the therapy regimen. Allergen immunotherapy may be especially beneficial when avoidance and medications no longer control the patient's symptoms.

Asthma

Allergic asthma often shares the same allergic triggers as allergic rhinitis. Allergen exposure in sensitive persons is an important cause of asthma symptoms and exacerbations.

When standard control and avoidance measures are not effective, specific allergy testing may be helpful.

The second National Heart, Lung, and Blood Institute (NHLBI) guideline on asthma management recommends that all asthma patients who require daily therapy be evaluated for allergens as possible contributing factors.¹⁰ They also note that, in selected patients with asthma at any level of severity, specific allergy testing may be indicated as a basis for allergen avoidance or immunotherapy. These recommendations would lead to a limited number of allergy tests in about one half of asthma patients, according to guideline predictions. As mentioned previously, the NHLBI notes that specific allergy testing may be particularly helpful in justifying the expense and effort involved in avoidance measures. In addition, it could help promote patient compliance in maintaining environmental controls (e.g., with regard to pets).

The author indicates that he does not have any conflicts of interest. Sources of funding: none reported.

REFERENCES

1. Lasley MV, Shapiro GG. Testing for allergy. *Pediatr Rev* 2000;21:39-43.
2. Valyasevi MA, Maddox DE, Li JT. Systemic reactions to allergy skin tests. *Ann Allergy Asthma Immunol* 1999;83:132-6.
3. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). *J Allergy Clin Immunol* 1987;79:660-77.
4. Carter ER, Pulos E, Delaney J, Matheson EJ, Moffitt DR. Allergy history does not predict skin test reactivity in asthmatic children. *J Asthma* 2000;37:685-90.
5. Li JT, Andrist D, Bamlet WR, Wolter TD. Accuracy of patient prediction of allergy skin test results. *Ann Allergy Asthma Immunol* 2000;85:382-4.
6. Wood RA, Phipatanakul W, Hamilton RG, Eggleston PA. A comparison of skin prick tests, intradermal skin tests, and RASTs in the diagnosis of cat allergy. *J Allergy Clin Immunol* 1999;103:773-9.
7. Sampson HA, Ho DG. Relationship between food-specific IgE concentrations and the risk of positive food challenges in children and adolescents. *J Allergy Clin Immunol* 1997;100:444-51.
8. Sogn DD, Evans R 3d, Shepherd GM, Casale TB, Condemi J, Greenberger PA, et al. Results of the National Institute of Allergy and Infectious Diseases collaborative clinical trial to test the predictive value of skin testing with major and minor penicillin derivatives in hospitalized adults. *Arch Intern Med* 1992;152:1025-32.
9. Solley GO, Gleich GJ, Van Dellen RG. Penicillin allergy: clinical experience with a battery of skin-test reagents. *J Allergy Clin Immunol* 1982;69:238-44.
10. National Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma: expert panel report 2. NIH publication no. 98-4051, Bethesda, Md., 1997:43,45.